CCL2 and myeloid sarcoma: Anti-CCL2 neutralizing antibody reduced mononuclear cell infiltration into the CNS and clinical severity in a mouse model of EAE (51, 58, 59). CCL2 KO mice exhibited less severe EAE clinical manifestations. In patients, CCL2 is expressed by astrocytes and macrophages in acutely demyelinating lesions and active chronic lesions. CCL2 levels in the CNS are reduced during increased disease activity in MS (60).